Literature DB >> 29724980

Author`s Reply.

Abdulcebbar Şipal1, Serdar Bozyel, Müjdat Aktaş, Emir Derviş, Tayyar Akbulut, Onur Argan, Umut Çelikyurt, Dilek Ural, Tayfun Şahin, Ayşen Ağır, Ahmet Vural.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29724980      PMCID: PMC6280259     

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We would like to thank the authors for their valuable comments on our recently published study titled “Surface electrogram-guided left ventricular lead placement improves response to cardiac resynchronization therapy” (1). Compared with group 2 (conventional LV lead placement group), group 1 (ECG-guided LV lead placement group) had a greater proportion of clinical responders; however, no significant differences were found (85% vs. 70%, p=0.181). In contrast, group 1 had a significantly higher rate (85% vs. 50%, p=0.02) of echocardiographic response to cardiac resynchronization therapy (CRT). CRT is an established therapy for heart failure patients with reduced LV ejection fraction and prolonged QRS duration, leading to important improvements in LV function and prognosis. However, up to 30% of patients do not respond to CRT. In group 1, both clinical and echocardiographic responses were found to be 85%. Therefore, the newly applied method can be considered useful for patients with multiple target veins. CRT helps to restore dyssynchrony, improves LV function, reduces functional mitral regurgitation, and induces LV reverse remodeling (2, 3). Since the mechanism of benefit is rather heterogeneous, a clear definition of response to CRT remains to be established, and both echocardiographic and clinical end-points can be used. As such, “identifying optimal predictors” used to define a favorable response remains a challenge. Furthermore, whether patients with clinical response also improve in echocardiographic end-points remains unknown (4). Bleeker et al. (5) have evaluated the correlation between clinical and echocardiographic improvement and have found discordance between the clinical response and >15% LVESV reduction as well as discordance in the clinical response and >5% absolute LVEF improvement. Despite such a discordance, it should be noted that the echocardiographic response rate was significantly low (50%) in group 2.
  5 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy.

Authors:  Gabe B Bleeker; Jeroen J Bax; Jeffrey Wing-Hong Fung; Ernst E van der Wall; Qing Zhang; Martin J Schalij; Joseph Yat-Sun Chan; Cheuk-Man Yu
Journal:  Am J Cardiol       Date:  2005-11-28       Impact factor: 2.778

3.  Gauging the response to cardiac resynchronization therapy: The important interplay between predictor variables and definition of a favorable outcome.

Authors:  Milan Petrovic; Marija Petrovic; Goran Milasinovic; Bosiljka Vujisic Tesic; Danijela Trifunovic; Olga Petrovic; Ivana Nedeljkovic; Ivana Petrovic; Marko Banovic; Marija Boricic-Kostic; Jelena Petrovic; Ross Arena; Dejana Popovic
Journal:  Echocardiography       Date:  2017-01-11       Impact factor: 1.724

4.  Cardiac-resynchronization therapy for the prevention of heart-failure events.

Authors:  Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2009-09-01       Impact factor: 91.245

5.  Surface electrogram-guided left ventricular lead placement improves response to cardiac resynchronization therapy.

Authors:  Abdulcebbar Şipal; Serdar Bozyel; Müjdat Aktaş; Emir Derviş; Tayyar Akbulut; Onur Argan; Umut Çelikyurt; Dilek Ural; Tayfun Şahin; Ayşen Ağır; Ahmet Vural
Journal:  Anatol J Cardiol       Date:  2018-03       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.